Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arthritis Multiple Joint Clear all
Terminated Phase 2 Interventional Results available

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

NCT00655824
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ofatumumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

NCT00753454
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03304379
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Diclofenac, Celecoxib, Matching placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
71
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis

NCT01853033
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ABT-122, Placebo
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Lenexa, Kansas • Raleigh, North Carolina • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Jul 23, 2026, 9:29 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

NCT06917404
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Pentosan Polysulfate Sodium twice weekly, Placebo
Drug
Lead sponsor
Paradigm Biopharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
40
States / cities
Peoria, Arizona • Tucson, Arizona • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 9:29 AM EDT
Not listed Not applicable Interventional

SMR Stemless Reverse Vs SMR Reverse Shoulder System

NCT04697004
View directory record Official record
Conditions
Arthroplasty, Replacement
Interventions
Investigational Arm: SMR Stemless Reverse, Control Arm: SMR Reverse Shoulder System
Device
Lead sponsor
Limacorporate S.p.a
Industry
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis

NCT00426621
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Diclofenac Sodium Gel, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
35 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
64
States / cities
Mobile, Alabama • Tallassee, Alabama • Chandler, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2007 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

Comparison of Alignment Achieved Using the VELYS Robotic-Assisted Solution Versus Manual Instrumentation in Total Knee Arthroplasty

NCT04730271
View directory record Official record
Conditions
Osteo Arthritis Knee, Osteoarthritis
Interventions
Total Knee Replacement
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
22 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Baltimore, Maryland • Crosby, Minnesota • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee

NCT00928837
View directory record Official record
Conditions
Osteoarthritis
Interventions
Flavocoxid 500 mg, Naproxen, Placebo, flavocoxid 250 mg
Dietary Supplement · Drug · Other
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
35 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Jul 23, 2026, 9:29 AM EDT
Completed No phase listed Observational

Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test

NCT03810144
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Vectra MBDA Test
Genetic
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Annapolis, Maryland • Baltimore, Maryland • Catonsville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

e-Mobile Tablet for People With Chronic Conditions

NCT02833311
View directory record Official record
Conditions
Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome, Parkinson's Disease
Interventions
Computer Tablet Group, Paper and Pencil Group, Contact Control Group
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 76 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Jul 23, 2026, 9:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

NCT02683239
View directory record Official record
Conditions
Osteoarthritis of the Knee or Hip
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 2 Interventional

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

NCT02267642
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AbGn-168H
Biological
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Health Promotion and Wellness Program for Adults With Disabling Conditions

NCT01776034
View directory record Official record
Conditions
Stroke, Multiple Sclerosis, Rheumatoid Arthritis
Interventions
SystemCHANGE Group Lifestyle counseling, Phone Lifestyle Counseling
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

NCT02291029
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 23, 2026, 9:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

MRI Markers of Cartilage Damage in Knee With Osteoarthritis

NCT00820430
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Magnetic Resonance Imaging
Other
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
5
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Efficacy & Safety Study Evaluating Natural Eggshell Membrane (NEM) in the Treatment of Osteoarthritis

NCT00750477
View directory record Official record
Conditions
Osteoarthritis
Interventions
NEM, Placebo
Dietary Supplement
Lead sponsor
ESM Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Cuba, Missouri • Kirksville, Missouri • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Jul 23, 2026, 9:29 AM EDT
Recruiting Phase 2 Interventional

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

NCT05986292
View directory record Official record
Conditions
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Interventions
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis

NCT00303056
View directory record Official record
Conditions
Joint Disease
Interventions
HOE140 Icatibant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

NCT00405275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, methotrexate, Sulfasalazine, Hydroxychloroquine, Placebo, triple, Placebo, etanercept
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Loma Linda, California • Long Beach, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Phase 2 Interventional

A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

NCT01851070
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Allogeneic Mesenchymal Precursor Cells, Normal Saline
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
20
States / cities
Anniston, Alabama • Gilbert, Arizona • El Cajon, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Jul 23, 2026, 9:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Home-based NMES Therapy for Knee Osteoarthritis Pain

NCT04128618
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CyMedica e-vive NMES
Device
Lead sponsor
CyMedica Orthopedics, Inc
Industry
Eligibility
21 Years to 85 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Jul 23, 2026, 9:29 AM EDT